Status:
NOT_YET_RECRUITING
REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study
Lead Sponsor:
Ruijin Hospital
Conditions:
Interstitial Lung Disease (ILD)
Eligibility:
All Genders
40-75 years
Phase:
PHASE1
Brief Summary
This clinical trial evaluates the safety and efficacy of REGEND001, an autologous bronchial basal layer stem cell therapy, in patients with interstitial lung disease (ILD). The treatment involves harv...
Eligibility Criteria
Inclusion
- Age 40-75 years.
- Confirmed diagnosis of ILD (e.g., IPF, connective tissue disease-associated ILD).
- DLCO ≥30% and \<80% predicted.
Exclusion
- Pregnancy, lactation, or plans for pregnancy within 1 year.
- Active malignancy or history of malignancy.
- Positive serology for HIV, HBV, HCV, or syphilis.
Key Trial Info
Start Date :
June 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06998706
Start Date
June 30 2025
End Date
June 30 2026
Last Update
May 31 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.